Takara Bio Swings to Deep Loss, Confirms Forecast and Scraps Dividend

The latest announcement is out from Takara Bio Inc. ( (JP:4974) ).

Takara Bio reported consolidated net sales of ¥28.39 billion for the nine months ended December 31, 2025, down 3.0% year on year, and posted operating and ordinary losses of ¥4.85 billion and ¥5.09 billion, respectively. Profit attributable to owners of parent deteriorated sharply to a ¥9.62 billion loss, compared with a ¥1.37 billion loss a year earlier, driving basic earnings per share down to negative ¥79.89 and reducing the equity ratio to 77.4% from 92.2% at the previous fiscal year-end.

The company maintained its full-year forecast for fiscal 2025, projecting a 6.5% decline in net sales to ¥42.1 billion and a net loss of ¥9.0 billion, and it plans to pay no interim or year-end dividends, versus a ¥17 per-share dividend in the prior year. During the period Takara Bio expanded its consolidation scope by adding Curio Biosciences, Inc., signaling ongoing strategic investment despite deepening losses, a weaker balance sheet, and suspended shareholder returns, developments that may heighten investor focus on execution and turnaround prospects.

The most recent analyst rating on (JP:4974) stock is a Sell with a Yen747.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.

More about Takara Bio Inc.

Takara Bio Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange that develops and sells research reagents, gene therapy technologies, and related products. The company focuses on life sciences and genomic research markets, supplying tools and services to academic, medical, and industrial customers worldwide.

Average Trading Volume: 275,771

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen98.38B

Find detailed analytics on 4974 stock on TipRanks’ Stock Analysis page.